Boston's Watchman approval on knife edge as panel vote nears
This article was originally published in Clinica
Executive Summary
It has been a long road, but US approval of Boston Scientific’s Watchman stroke-prevention device for atrial fibrillation patients is still far from assured. The left atrial appendage (LAA) closure device is due to be reviewed by an FDA advisory panel on 11 December, and the agency has put out briefing documents that are decidedly mixed, raising doubts over its eventual approval.